Estrogen and the skeleton

Trends in Endocrinology and Metabolism

Volumn 23, Issue 11, 2012, Pages 576-581

  Khosla, Sundeep ^a   Oursler, Merry Jo ^a   Monroe, David G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE METABOLISM; BONE REMODELING; BONE TURNOVER; ESTROGEN DEFICIENCY; HORMONE RESPONSE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SKELETON;

ANIMALS; BONE AND BONES; BONE REMODELING; ESTROGENS; FEMALE; HUMANS; MALE; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; OSTEOPOROSIS; T-LYMPHOCYTES;

EID: 84867142227     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.03.008     Document Type: Review

References (56)

1. Albright F. Post-menopausal osteoporosis. Trans. Assoc. Am. Physicians 1940, 55:298-305.
2. Khosla S., et al. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J. Bone Miner. Res. 2011, 26:441-451.
3. Lindsay R., et al. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976, i:1038-1040.
4. Khosla S., et al. Osteoporosis in men. Endocr. Rev. 2008, 29:441-464.
5. Falahati-Nini A., et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 2000, 106:1553-1560.
6. Hannon R., et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J. Bone Miner. Res. 1998, 13:1124-1133.
7. Lufkin E.G., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. 1992, 117:1-9.
8. Garnero P., et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 1996, 11:337-349.
9. Hauge E.M., et al. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J. Bone Miner. Res. 2001, 16:1575-1582.
10. Andersen T.L., et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am. J. Pathol. 2009, 174:239-247.
11. Bonewald L.F. The amazing osteocyte. J. Bone Miner. Res. 2011, 26:229-238.
12. Xiong J., et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 2011, 17:1235-1241.
13. Nakashima T., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 2011, 17:1231-1234.
14. Kearns A.E., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008, 29:155-192.
15. Tang Y., et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 2009, 15:757.
16. Baron R., et al. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
17. Zhao C., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006, 4:111-121.
18. Negishi-Koga T., et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med. 2011, 17:1473-1480.
19. Pederson L., et al. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. U.S.A. 2009, 105:20764-20769.
20. Favus M.J. Bisphosphonates for osteoporosis. N. Engl. J. Med. 2010, 363:2027-2035.
21. Cummings S.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 2009, 361:756-765.
22. Tomkinson A., et al. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 1997, 82:3128-3135.
23. Tomkinson A., et al. The role of estrogen in the control of rat osteocyte apoptosis. J. Bone Miner. Res. 1998, 13:1243-1250.
24. Emerton K.B., et al. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 2010, 46:577-583.
25. Marathe N., et al. Pro-survival effects of 17beta-estradiol on osteocytes are mediated by NO/cGMP via differential actions of PKG I and II. J. Biol. Chem. 2011, 287:978-988.
26. Imai Y., et al. Estrogen receptor alpha expression in osteocytes is necessary to maintain normal bone mineral density and reduce bone loss due to unloading. J. Bone Miner. Res. 2011, 26(Suppl. 1). abstract FR0310.
27. Oursler M.J., et al. Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:6613-6617.
28. Nakamura T., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of fas ligand in osteoclasts. Cell 2007, 130:811-823.
29. Martin-Millan M., et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol. Endocrinol. 2010, 24:323-334.
30. Shevde N.K., et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7829-7834.
31. Huber D.M., et al. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001, 142:3800-3808.
32. Srivastava S., et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kB ligand (RANKL)-induced JNK activation. J. Biol. Chem. 2001, 276:8836-8840.
33. Robinson L.J., et al. Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor alpha with BCAR1 and Traf6. Exp. Cell Res. 2009, 315:1287-1301.
34. Eghbali-Fatourechi G., et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003, 111:1221-1230.
35. Hofbauer L.C., Khosla S., et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
36. Khosla S., et al. Estrogen and testosterone have opposite effects on circulating OPG levels following induction of hypogonadism and aromatase inhibition in normal elderly men: potential mechanism for differential effects of estrogen versus testosterone on bone resorption. J. Bone Miner. Res. 2001, 16(Suppl. 1):S146.
37. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 1995, 332:305-311.
38. Pacifici R., et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:5134-5138.
39. Tanaka S., et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 1993, 91:257-263.
40. Kimble R.B., et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 1994, 93:1959-1967.
41. Ammann P., et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 1997, 99:1699-1703.
42. Kimble R.B., et al. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1-and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 1996, 271:28890-28897.
43. Kitazawa R., et al. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 1994, 94:2397-2406.
44. Charatcharoenwitthaya N., et al. Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women. J. Bone Miner. Res. 2007, 22:724-729.
45. Roggia C., et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13960-13965.
46. Cenci S., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-a. J. Clin. Invest. 2000, 106:1229-1327.
47. Sass D.A., et al. The role of the T-lymphocyte in estrogen deficiency osteopenia. J. Bone Miner. Res. 1997, 12:479-486.
48. Lee S.K., et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J. Bone Miner. Res. 2006, 21:1704-1712.
49. Kousteni S., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730.
50. Kousteni S., et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 2003, 111:1651-1664.
51. Almeida M., et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J. Biol. Chem. 2007, 282:27285-27297.
52. Manolagas S.C., Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol. Endocrinol. 2007, 21:2605-2614.
53. Chang J., et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat. Med. 2009, 15:682-689.
54. Modder U.I.L., et al. Regulation of circulating sclerostin levels by sex steroids in women and men. J. Bone Miner. Res. 2011, 26:27-34.
55. Iyer S., et al. ERalpha-deletion from osteoblast progenitors abolishes the protective effect of estrogens on cortical bone mass in both female and male mice. J. Bone Miner. Res. 2011, 26(Suppl. 1). Abstract 1110.
56. Callewaert F., et al. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J. Endocrinol. 2010, 207:127-134.